Full Text Journal Articles from
Abstract 20713299


Find full text journal articles

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

PMID: 20713299 (view PubMed database entry)
DOI: 10.1016/j.ygyno.2010.07.004 (read at publisher's website )
PMCID: PMC4568837 (free full text version available)

Download PDF Download PDF

Arthi Vijayaraghavan, Molly B Efrusy, Karyn A Goodman, Christopher C Santas, Warner K Huh,

<h4>Objective</h4>Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology. Our objective was to determine the cost-effectiveness of adding HPV-16 and 18 genotype triage to current cervical cancer screening strategies in the United States.<h4>Methods</h4>We developed a lifetime Markov model to assess the cost-effectiveness of the following cervical cancer screening algorithms: (1) liquid-based cytology (LBC), (2) LBC+HPV triage, (3) HPV+LBC triage, (4) co-screening, (5) co-screening+HPV genotyping, and (6) HPV only+HPV genotyping. Costs were estimated from a payer perspective in 2007 U.S. dollars. Outcome measures included lifetime risk of cervical cancer, quality-adjusted life years saved (QALYs), and incremental cost-effectiveness ratios (ICERs).<h4>Results</h4>In our model, the use of HPV genotyping strategies prevented 51-73 deaths per 100,000 women screened compared to screening using LBC followed by HPV triage and 4-26 deaths compared to co-screening with LBC and high-risk HPV. Use of HPV genotyping to triage all high-risk HPV-positive women every three years had an ICER of $34,074 per QALY compared to HPV and LBC co-screening. HPV genotyping with co-screening was the most effective strategy and had an ICER of $33,807 per QALY compared to HPV genotyping for all high-risk HPV-positive women.<h4>Conclusion</h4>The addition of HPV-16 and -18 genotype triage to HPV and LBC co-screening was a cost-effective screening strategy in the United States.

Gynecol Oncol (Gynecologic oncology)
[2010, 119(2):237-242]

Cited: 10 times

AltMetric Statistics



0.6635 s